relipidated recombinant tissue factor, patient plasma showed markedly reduced binding t o tissue factor at all concentrations tested. In an effort t o separate the contributions of the two mutations, three recombinant variants, wild-type, R79Q, and R152Q. were prepared and analyzed. The R152Q variant had markedly reduced activity in a clotting assay, whereas R79Q showed a milder, concentration-dependent reduction. The R152Q variant exhibited nearly normal binding in the tissue factor binding assay, whereas the R79Q variant had markedly reduced binding. The time course of activation of the R790 variant was slowed compared with wild-type. Our results suggest that the first EGF-like domain is required for binding t o tissue factor and that the F.VII zymogen lacks activity and requires activation for expression of biologic activity. more rapidly in the presence of TF.5 The site(s) of interaction between F.VII and TF are not known with certainty; previous reports have suggested that the Gla domain,"* the EGF-like domains,"'" and the catalytic are required for interaction with TF.
Hereditary deficiency of F.VII was first reported by Alexander et a1 in 1951.14 Severe F.VII deficiency has an estimated incidence of 1 in 500,000; approximately 100 cases are described in the world's 1iterature.l'"' Molecular defects responsible for F.VII deficiency have been determined in only a few cases. These few cases include one patient with an F.VII activity level of 1.7%, who is a compound heterozygote for 2 frameshift mutations,'' and one patient with an F.VII activity level of 28%, who is homozygous for a mutation in the heavy chain, Arg 304 + Gln. Characterization of this patient's F.VII protein shows a reduced affinity for TF.I3 In addition, Marchetti et a12* have reported two patients with severe F.VII deficiency (F.VII 4%) associated with a Cys 310 "* Phe substitution. Whether this is the causative mutation in this instance is unclear, because the protein was not characterized or expressed, and only exons 6 to 8 were sequenced. These investigators also described another patient with a F.VII activity level of 40%, who was heterozygous for the Arg 304 -+ Gln mutation. Again, only exons 6 to 8 were characterized. 2" In this report, we describe the molecular basis of disease in a patient with severe F.VII deficiency. This patient is of particular interest because he is homozygous for 2 mutations, one at Arg 152 (R152Q) and the other at Arg 79 (R79Q). We have called this mutant molecule F.VIIch~,u,tc. Through characterization of the patient's plasma and of recombinant mutants containing either the R152Q mutation or the R79Q mutation, we show that the former mutation prevents activation of the F.VII zymogen, and the latter interferes with F.VII's interaction with TF.
MATERIALS AND METHODS

Patient history.
The patient is a 27-year-old black man with severe F.VII deficiency. He was the 5 lb. 7 oz. product of a 36-week gestation that was complicated by premature rupture of the membranes 56 hours before delivery. At birth, the child was noted to have a foul odor, and was reported to have an Apgar score of 3 (time not noted). At 20 hours of age, the child was noted to have a nosebleed. The prothrombin time (FT) was 51.6 seconds with a control of 1 1.5 seconds. Despite repeated administration of vitamin K, bleeding failed to stop, and the child was treated with a 50 mL transfusion of fresh blood, bleeding ceased and the hemoglobin (Hgb) increased from 9.5 to 15.2. Two weeks later, the child was noted to have a F T of 35 seconds and a Hgb of 12.7. Vitamin K was again administered. Four days later, epistaxis recurred. Hgb was found to be 6.6 and the patient received 60 mL of 5-day-old whole blood, with cessation of bleeding. The patient was transferred to the University of North Carolina Hospitals for further evaluation of his bleeding diathesis. There was no family history of bleeding disorders, and the mother denied any history of consanguinity. Physical examination of the infant was normal except for generalized increased tone and bilateral inguinal hernias. The PT was 45 seconds, the platelet count was 314,OOO/pL, and the bleeding time was 6 minutes. F.VII activity was less than 1%. Other factor levels were within normal limits. A diagnosis of severe F.VII deficiency was made and, based on the infant's neurologic status, an intracranial bleed during the first month of life was suspected. The child continued to manifest developmental delays, and at 22 months of age was unable to walk or talk, had constant nystagmus, and had spastic paraparesis of both lower extremities. At 31 months of age, he was admitted for further deterioration in neurologic status and on pneumoencephalogram was noted to have a mild communicating hydrocephalus and evidence of intracranial bleeding. He subsequently developed a severe scoliosis as a complication of his spastic paraparesis, necessitating, at age 14, anterior and posterior spine fusion with Luque rod instrumentation, under fresh frozen plasma
( F F F ' )
and prothrombin complex concentrate coverage. Despite repeated cauterizations, nosebleeds severe enough to require treatment with either FFF' or prothrombin complex concentrates have continued to occur approximately once a month throughout the patient's life. Generally, the patient has been free of other types of bleeding, although it should be noted that his level of activity is severely limited by his spastic paraparesis (he is confined to a wheelchair). Developmentally, he tests in the mildly retarded range and has learned to read, write, and speak.
Patient samples-DNA andproteinpurijication. After obtaining informed consent from the patient's mother, blood specimens were drawn from the patient and his mother. The father is unavailable for testing, and the patient has no full siblings. DNA was prepared from EDTA-anticoagulated specimens by the method of Bell et al.'' Citrated plasma specimens were used for F.VII antigen and activity determinations (vide infra). After Q-sepharose absorption, normal and patient F.VII were purified to homogeneity by immunoaffinity chromatography using a mouse monoclonal antibody (MoAb) that recognizes an epitope in the light chain" (gift of Dr Ulla Hedner and Dr Torben Lund-Hansen of Novo Nordisk, Gentofte, Denmark). Plasma F.VII antigen levels were determined in a sandwich enzymelinked immunosorbent assay (ELISA) using MoAbs provided by Novo Nordisk (Copenhagen, Denmark)."
Coagulation assays. PTs on plasma and purified recombinant protein were determined using one-stage clotting assays. The source of TF in these assays was rabbit brain and lung thromboplastin (Simplastin-300; Organon Teknika, Durham, NC). Plasma PTs were determined at dilutions ranging from 1:lO to 1:80. Purified recombinant proteins were initially diluted to 50 pg/mL with TBS-BSA buffer (0.05 m o m Tris, pH 7.5, 0.15 m o m NaC1, 1 mg/mL bovine serum albumin) and tested at serial dilutions ranging from 1:10 to 1:80 (the 1:80 dilution approximates plasma concentrations of F.VII). One hundred microliters of diluted sample or plasma was incubated with 100 pL of F.VII-deficient plasma (HRF, Inc, Burlington, NC); the assay was initiated with 200 pL of thromboplastin reagent. All samples and reagents were prewarmed at 37°C before use. Plasma F.VII activity levels were determined in a one-stage clotting assay using F.VII-deficient substrate. The normal range (60% to 150%) is determined by assaying plasma from 20 unaffected individuals.
Isolation and characterization of mutant F. VI1 gene. Based on published intron data,' eight pairs of oligonucleotides (shown in Table 1 ) were synthesized and used to perform enzymatic amplificationZ3 of the coding regions and exon-intron junctions of F.VII from the patient's DNA. Exons la and l b were amplified separately, and exons 3 and 4 were amplified as a single fragment. Target sequences were amplified in a 50 pL volume containing 0.2 pg genomic DNA, 10 mmom Tris-HC1, pH 8.3, 50 mmol/L KCl, variable concentrations (see Table 1 ) of MgC12, 0.01% (wt/vol) gelatin, 0.2 mmollL of each deoxyribonucleotide (dNTP, dATP, dCTP, dGTP, and dTTP), 0.1 p m o m of each primer, and 1.5 U Taq polymerase. The polymerase chain reaction (PCR) reaction mixture for exon 2 also included 5% (voVvol) dimethylsulfoxide (DMSO), which was required for optimal amplification.
The samples were overlaid with 50 pL mineral oil to prevent evaporation and subjected to 30 cycles of denaturation at 94°C for 2 minutes, annealing at 55°C for 2 minutes, and primer extension at 72°C for 3 minutes on a DNA Thermal Cycler R (Perkin-Elmer Cetus, Emeryville, CA). The amplified DNA was electrophoresed on a 2% agarose gel and the fragment was recovered.
Direct sequencing of PCR-amplified products was performed using the method of DuBose and DNA templates were denatured by boiling in the presence of 0.4% Nonidet P-40 (Sigma, St Louis, MO). Sequenase Version 2.0 (US Biochemical, Cleveland, OH) was used according to the manufacturer's instructions.
Restriction digests. To confirm results obtained by sequencing, and to screen normal controls for the same nucleotide changes, exon 4 was amplified as described above and digested with Msp I or its isoschizomer Hpa 11. Exon 6 was amplified as a 182-bp fragment. The reverse oligo for this application (5' GGCACACCTTKCCC-CCAGAATT 3') contains part of the recognition sequence for the enzyme EcoRI (underlined). All restriction enzymes were obtained from New England Biolabs (Beverly, MA) and digests were performed using manufacturer's suggested conditions. Digested DNA was electrophoresed on a 2% agarose gel (NuSieve GTG; Fh4C Corp, FMC BioProducts, Rockland, ME) in TBE buffer for the exon 4 analysis, and on a 3% NuSieve, 1% agarose gel for the exon 6 analysis. Exons 4 and 6 amplified from normal DNA were used as controls in all restriction digests.
Site-directed mutagenesis and in vitro expression. A modified human F.VII cDNA carrying a deletion of nt 100-165 (resulting in a 38 amino acid pre-pro leader sequence rather than a 60 amino acid one) was inserted into the multiple cloning site of the phagemid pMA254." Two separate mutant constructs were made, one containing the exon 4 mutation and the other the exon 6 mutation. Mutations were introduced into the pMA254-F.VII plasmid by oligonucleotide hybridization. 26 The presence of the point mutation in the mutagenized plasmid was confirmed by DNA sequence analysis. The plasmid pCMV5 was used as the expression vector." The normal F.VII cDNA was inserted into the multiple cloning site of this plasmid to express wild-type F.VII. The expression plasmids for the exon 4 and exon 6 mutations were constructed by excision of the entire F.VII cDNA as an EcoRI-Hind111 fragment, which was replaced with the corresponding fragment from the mutated pMA254-F.VII plasmid. The correct insertion of the fragment and the presence of the mutation were again confirmed by sequence analysis.
The human embryonic kidney cell line 293 (American Type Culture Collection, Rockville, MD) was cotransfected with the pCMV5 plasmids and pSV2neo by calcium phosphate transfection." Cells Cells were then grown ovemight in identical medium except that FCS was removed. Colonies were screened for levels of production by ELISA. Two hundred and fifty microliters of the overnight conditioned medium was coated on a microtiter plate at 4°C overnight. After blocking the noncoated sites with 6% BSA solution, the coated microtiter plate was incubated with 100 p L of diluted MoAb against F.VII light chain, followed by 100 pL of goat antimouse IgG (Fab specific) Biotin conjugate (Sigma) and 100 pL of anti-Biotin-peroxidase (Sigma). The color was developed after adding o-phenylenediamine and H202 substrate solution. The reaction mixtures were measured at 490 nm after stopping the reaction with 50 pL of 2.5 moll L H2S04. The highest producers were selected for further expansion. Gla analysis was performed on purified proteins (vide infra), and only clones expressing appropriately carboxylated material were selected for further study. Purification of wild-type, R79Q, and R152Q F.VI1 from conditioned medium. The selected R79Q F.VII or R152Q F.VII producing cell lines were cultured in D M E W 1 2 medium containing 2% to 10% FCS, penicillidstreptomycin, and 5 pg/mL vitamin K. The pooled material was concentrated by centriprep-30 concentrators (Amicon, Beverly, MA). The concentrations of purified protein were determined by the Bio-Rad protein assay system (Bio-Rad Laboratories, Hercules, CA). Samples were run on a 10% polyacrylamide gel and silver stained.
Cla analysis. Analysis for y-carboxyglutamic acid content (Gla analysis) was performed according to the method of ~rice.2~ Determinations were performed in duplicate, and results are reported as an average. N-terminal sequence analysis, using W a n degradation, was performed to confirm the presence or absence of y-carboxylglutamic acid at specific residues in the N-terminus.
For functional assays described, only mutant protein with Gla content similar to that of wild-type was used for analysis. Analysis for &hydroxy aspartic acid content was performed by the method of Przysiecki et al.Jo TF binding assay for plasma and for recombinant F. VU. Recombinant TF apoprotein was provided by Genentech, Inc (South San Francisco, CA) and was relipidated using a modification of previously published procedures." Essential features of the procedure include oxidation of the apoprotein in the presence of CuS04, preparation of a lipid suspension containing phosphatidylcholine and phosphatidylserine, addition of the apoprotein to the lipid suspension in a ratio of 1:42,000, and dialysis of the mixture against dilute TBS. The dialysis step removes detergent, causing lipid vesicle formation, and the TF apoprotein becomes incorporated into a lipid bilayer. Relipidated recombinant human TF (oxidized) is coated onto Immulon I1 plates in carbonate antigen coating buffer overnight at 4°C
(1 1.5 ng TF per well in 100 pL). BSA (100 ng) is coated onto plates under the same conditions for use as a control. The plates are then washed and nonspecific binding sites blocked by the addition of 400 pL of 2 mg/mL BSA in TBS-T buffer (10 mmol/L Tris, pH 8,0.15 m o w NaC1, 0.025% tween-20, 10 mmol/L CaCl,) for 2 hours at room temperature.
After three washes, 100 pL of diluted human plasma samples (1:30 to 1:500 dilutions) were added in triplicate to TF-and BSAcoated wells and incubated for 2 hours at room temperature (RT). Plasma samples contained 25 U/mL heparin and 25 mmol/L benzamidine. For assays on purified recombinant F.VII variants, protein samples were adjusted to 450 ng/mL zymogen F.VII and then serially diluted in TBS-T buffer. After additional washes, monospecific p l y -clonal rabbit antihuman F.VII sera (Diagnostica Stago, Guelph, Ontario) was added and incubated for 1 hour at RT. Goat antirabbit IgG (H + L; Jackson Immuno Research Labs, West Grove, PA) conjugated to alkaline phosphatase, followed by the alkaline phosphatase substrate PNPP, was used for detection. The plates were read at 405 nm in an automatic microplate reader (Model EL309; BioTek Instruments, Burlington, VT). After subtraction of background (routinely less than 0.1 OD U), the absorbance at 405 nm was taken to be directly proportional to the degree of F.VII binding to the immobilized TF. For plasma samples, binding was expressed as a percentage of the result for normal pooled plasma at the same dilution.
Activation ofF.VI1 with human F.Xa. Purified recombinant proteins were made 1 m g / d in BSA and dialyzed into TBS-BSA, pH 7.5, buffer to remove benzamidine. Recombinant VI1 (wild-type, R79Q, or R152Q) at 200 nmoVL was incubated with 400 pmoVL purified phospholipid vesicles (30% phosphatidylserine, 70% phosphatidylcholine), 5 mmoVL Ca", and 20 m o V L F.Xa (Enzyme Research Laboratories, South Bend, IN). The reaction was perfonned in 0.2 mL total volume of TBS-BSA, pH 7.5. At selected time intervals, 30 pL of reaction mixture were removed and subjected to 12% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE). After electrophoresis, the proteins were electrophoretically transferred to nitrocellulose membranes. The membranes were incubated with diluted MoAb against F.VII light chain and rabbit plyclonal antibody against F.VII, then with biotinylated antimouse IgG and antirabbit IgG followed by avidin-peroxidase complex (Vector Laboratories, Burlingame, CA). The purified normal or mutated factor VIWIIa and degradation products were visualized by an enhanced chemiluminescence detection system (Amersham. Arlington Heights, L). Purified plasma-derived F.VII was activated and visualized in the same manner.
To determine rate constants, rF.VIIs were activated as described above. At timed intervals, 10-p1 samples were removed and added to 40 @L buffer containing EDTA in a small excess over calcium. After all samples were collected, the amount of active F.VII was measured by adding 50 pL of an assay solution that contained 1 mmol/L S2266 (Helena Laboratories, Beaumont, TX), 0.1 mmoVL TenStop (American Diagnostica, Greenwich, CT), 60 nmoVL TF apoprotein, and 8 mmol/L CaCI2. The reaction was monitored for 10 minutes in a microplate reader. Data were fitted to the equation3': mg/mL albumin for 5 minutes at room temperature. Fifty microliters of S2266 was added in the same buffer and the rate of substrate cleavage was measured for 10 minutes at 405 m. The rate of substrate cleavage was directly related to the concentration of F.VIIa/ TF complex. A11 samples were run in duplicate. The data were fitted to the following equation.
Rate,, is the rate of substrate cleavage in the absence of TF, Rat%, is the maximum rate of substrate cleavage, TF is the concentration 
RESULTS
Coagulation profile of patient and mother. The PT and F.VII antigen and activity levels are shown in Table 2 . The patient has a markedly prolonged PT. Antigen levels for both the patient and his mother fall within the normal range. The patient has no detectable F.VII activity; his mother has an activity level of 66%. a midrange value that, by itself, is not clearly diagnostic of either the carrier (heterozygous for the causative mutation) or the normal state. The mother has no history of bleeding diathesis.
Isolation and characterization of the mutant F. VI1 gene. Sequence analysis of the coding region and the exon-intron junctions showed two distinct mismatches when compared with the normal sequence. The first, a G + A transition at nucleotide 6055 in exon 4 (numbering as in O'Hara et al'), results in the substitution of Gln for Arg at amino acid 79.
The second, a G + A transition at nucleotide 8961 in exon 6, also changes an Arg to a Gln at amino acid 152, the cleavage site for generation of the active species F.VIIa. Direct sequencing shows that the patient is homozygous for the exon 4 and exon 6 mutations (Fig 1) and that the mother is heterozygous for both (data not shown).* These findings were confirmed by restriction analysis. For the exon 4 mutation, the G 4 A change abolishes the recognition site for the enzyme Msp I (and its isoschizimer Hpa 11). Amplification of a 398-bp fragment containing exon 4, followed by digestion with Msp I, results, for the wild-type sequence, in the generation of 3 fragments of 294, 85, and 19 bp. The presence of the mutation aiters this to 2 fragments of 379 and 19 bp. As shown in Fig. 2 , analysis of the mother's DNA generates both the 379-and the 294-bp fragments, indicating * Preliminary reports from this laborat~rY*J~*~ did not describe homozygosity of the exon 6 mutation. This was likely due to a PCR contamination error, because subsequent sequencing and restriction analysis have unequivocally demonstrated homozygosity at this locus. that she is heterozygous for the exon 4 mutation. The patient, in lanes 4 through 6, shows only the 379-bp fragment; thus, he is homozygous for the exon 4 mutation. A normal control, in lanes 7 through 9, shows only the 294-bp fragment (the 85-bp fragment is not clearly visible on the gel). For the exon 6 mutation, a reverse oligo was synthesized that contains 5 of the 6 residues (GAATT) of the EcoRI recognition site.
In the presence of the normal sequence, the EcoRI site is completed by the C in the lower strand, but in the mutant sequence, with a T in the lower strand, no EcoRI site is created (Fig. 3A) . Amplification and digestion with EcoRI of a 182-bp fragment containing exon 6 is shown in Fig 3B. For patient DNA, in lane I, the 182-bp fragment is unchanged after EcoRI digestion. For the normal control, the 182-bp fragment is reduced to a 159-bp fragment. For the mother, who is heterozygous, both bands are clearly visible. The patient, then, is homozygous for the exon 6 mutation; his mother is heterozygous. There are no full-length reports of naturally occurring variants at the exon 6 locus. However, Wildgoose et al "
have prepared and analyzed a recombinant F.VII mutant, R152E, and showed that this molecule cannot be activated and lacks coagulant activity. Based on their analysis, it seemed likely that the homozygous R152Q mutation in this patient would account for the patient's F.VII activity of less than 1 %. It was unclear initially whether the exon 4 nucleotide substitution represented a mutation or simply a polymorphism. We therefore screened 43 normal individuals (86 alleles) with amplification and digestion by Msp I. This analysis showed that no individuals other than the two reported herein had the exon 4 nucleotide change. These data, in conjunction with functional data on the R79Q recombinant (vide infra), strongly suggest that the exon 4 substitution does not represent a polymorphism. Characterization of patient plasma-derived F. Vll. In addition to standard clotting assays, two other types of analysis were done on the patient's plasma. In the first, F.VII was purified from patient plasma and activated in vitro with (lanes 1 and 2) , activation converts the 50-kD single-chain form to lower molecular weight (MW) bands, the heavy chain, visible at 30 kD, and the light chain, at 20 k D , not seen on the Western blot. However, for patient F.VII, incubation with F.Xa and cofactors leaves the material essentially unchanged. Lanes 3 and 4 show a small amount of a lower MW form (~~4 0 kD). This pattern is similar to that observed by Wildgoose et a134 on analysis of a recombinant mutant, R152E, which cannot be cleaved at the activation site. The location of the peptide bond cleaved to generate the 40-kD form was not established in that investigation or in the current work.
In the second assay, the binding of patient F.VII to tissue factor was tested in an in vitro system. Plasma samples from the patient and his mother were diluted in TBS-T and applied to Immulon I1 plates that had been coated with relipidated recombinant TF. After incubation and washing to remove nonspecific binding, bound F.VII was measured using polyclonal rabbit antihuman F.VII sera. Binding by the propositus' plasma was less than 10% normal at all dilutions tested (Fig. 5) . The mother's plasma was intermediate between normal pooled plasma and the patient's; her binding is approximately 68% of the value for pooled plasma.
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Preparation, purification. and characterization of recombinant F. VI1 variants. Based on the characterization of the R152E recombinant mutant,34 we hypothesized that the R152Q mutation alone would result in a species with little or no coagulant activity. Thus, whether the R79Q substitution has any effect on coagulant activity cannot be established solely from a study of the plasma-derived material. In an effort to separate the effects of the two mutations, we prepared two distinct recombinant F.VII molecules (in addition to wild-type), one containing the exon 4 mutation (R79Q) and the other the exon 6 mutation (R152Q). The three recombinant species were purified to near homogeneity from 293 cell conditioned medium, as shown in the silverstained SDS gel in Fig 6. The recombinant F.VII species all had identical apparent MWs. An initial difficulty in the purification was the unintentional activation of rVII to rVIIa during the chromatography step. This was solved by the addition of benzamidine to the conditioned medium and to all the solutions used in the purification steps. Before analysis of the recombinant proteins, benzamidine was removed by dialysis. The specific activity of the recombinant proteins, based on activity in coagulation assays (vide infra), was 1,600 U/mg protein for wild-type F.VII, 150 U/mg protein for R79Q, and 0 U/mg protein for R152Q. After activation, wild-type and R79Q had comparable amidolytic activity, as measured by ability to cleave S2266, in the absence of TF.
The amidolytic activity of both species was identical to that of plasma-derived VIIa in the absence of tissue factor (1.23 mol p-nitroanilide/minute/mol VIIa).
Gla analysis. Amino acid analysis showed that neither the Gla content nor the P-hydroxyaspartic acid content of the mutant F.VIIs varied significantly from the content of the recombinant wild-type protein. R79Q analyzed for 7.42 mol Gla/mol protein, R152Q for 7.31 mol Gla/mol protein, and wild-type for 7.24 mol Gla/mol protein. To establish that there was no difference in carboxylation among the proteins at specific Gla residues, N-terminal sequence analysis was performed on wild-type and R79Q. Analysis through 30 cycles, including 9 of the I O Gla residues, demonstrated 290% carboxylation at each residue in wild-type and in R79Q. Thus, there appear to be no specific residues that are undercarboxylated. Interestingly, the recombinant species tested had 0.15 to 0.18 mol P-hydroxyaspartic acid/mol protein; plasma-derived F.VII generally does not contain this modified amino acid, which is found in F.IX and F.X.
Coagulation assays in reconstituted plasma. Purified recombinant proteins in varying concentrations were added to hereditary F.VII deficient plasma and prothrombin times determined. The results are displayed in Table 3 . The values in the second row, at a concentration of 625 ng/mL, are closest to a physiologic concentration (397 to 790 ng/mL). The R152Q mutation yields markedly prolonged P T s at all concentrations tested. The R79Q mutation yields prolonged P T s at physiologic concentrations, but the PT progresses toward normal as the concentration of the mutant F.VII increases; at I O times physiologic concentration, the R79Q protein gives a normal result. Thus, the defect in the R79Q protein can be overcome by increasing the concentration of the protein but that of the R152Q mutant cannot.
TF binding to recombinant proteins. Purified recombinant proteins were diluted in buffer and assayed for binding to recombinant relipidated TF. For the wild-type protein, results were linear over the concentrations tested; results for the RI 524 mutant protein were essentially identical to wildtype (Fig 7) . For the R79Q mutant protein, binding to TF was markedly reduced, to =IO% to 15% of that for wildtype. This result was observed for all concentrations tested.
Time course of activation. Under identical activation conditions, the R79Q variant activated more slowly than the wild-type F.VII (Fig 8) . Determination of rate constants (k) for activation showed a k of 0.2 min" for the wild-type and 0.13 min" for the R79Q variant.
Activity of Vlla. Wild-type and R79Q recombinant F.VIIs were activated by Xa as described above, except that activation was allowed to proceed for 4 hours, to insure complete conversion of VI1 to VIIa. (Preliminary experiments, in which the activity of material for functional characterization had been monitored by S2266 cleavage, showed no loss of activity of VIIa when compared with shorter acti-HC + 1 2 3 4 Table 1 of Sridhara et al?'
vation times.) In the presence of a large excess of TF, there was no difference between the two species in the ability to cleave the synthetic substrate S2266 or to cleave X to generate Xa. At lower concentrations of tissue factor, there was a clear difference between wild-type and R79Q in ability to cleave S2266 (Fig 9) . In the absence of TF, the two species were again equivalent.
DISCUSSION
Isolation of this patient's plasma-derived F.VII allows study of a species containing two defects, R79Q and R152Q. Our experimental strategy was to prepare recombinant mole- cules containing one or the other of the patient's defects, and thus attempt to define how each defect affects the function of F.VII. The naturally occurring variant, and the recombinant proteins synthesized to elucidate its defects, have implications for two critical aspects of the function of F.VII: (1) whether F.VII that cannot be activated to VIIa has activity in coagulation, and (2) what regions of F.VIIa are required for interaction with TF. The clinical, genetic, and biochemical data generated in this study yield insight into both of these questions.
Severe F.VII deficiency is a rare disorder. Most descriptions in the literature are clinical case r e p~r t s '~"~+ '~-~~ that include activity but not antigen levels, and it is therefore difficult to estimate the frequency of mutations such as F.VIIch,lo,,., in which the antigen level is normal but the activity level is severely reduced. The literature contains only one previous report of a gene defect associated with severe F.VII deficiency (~2 % activity); the affected patient is a compound heterozygote with 2 distinct frameshift mutations in the region encoding the heavy chain. The F.VII activity level is 1.7%; a reduced antigen level of only 1.2% precluded any characterization of the mutant protein in that case.I9 Based on data in previous case reports, this patient's clinical course appears typical for an individual with severe F.VII deficiency. Epistaxis is quite common in these patients, and intracranial bleeding in infancy is also reported.I5 An unusual feature of our patient's case is the presence of two distinct nucleotide substitutions in the F.VII gene, with the patient being homozygous for both. The patient's mother is heterozygous for both changes; she denies any history of consanguinity, but the father is unavailable for testing. Given the CHAING ET AL low prevalence of F.VII deficiency in the population, it seems unlikely that the patient has inherited two independent alleles each carrying two mutations, and the overwhelming likelihood is that the patient is the product of a consanguineous union, despite the mother's history. Another possibility is that the patient has one allele carrying both mutations (inherited from the mother) and a deletion of the second allele (inherited from the father), ie, that he is hemizygous rather than homozygous. Whatever the case. the patient is functionally homozygous, because the plasma contains only a single species of F.VII, which is encoded by a gene with mutations at exons 4 and 6.
An initial hypothesis was that the exon 4 substitution (R79Q) might represent a polymorphism, but screening of 86 normal alleles failed to show any with this nucleotide substitution, and subsequent study of a recombinant mutant carrying the R79Q substitution disclosed defective clotting activity, so it seems unlikely that the exon 4 change is a polymorphism.
Our working hypothesis, subsequently proved correct, was that the R152Q mutation encodes a protein with very little activity in coagulation. This hypothesis is based on two lines of evidence. First, analysis of a recombinant mutant, R152E, which lacks the Arg residue at the cleavage site for activat i~n ,~~ showed that it had no clotting activity after incubation with either IXa or Xa. These data suggest that the loss of the Arg at 152 results in a protein that cannot generate the normal activated VIIa species. Second. if the molecule cannot be cleaved, it is unlikely to have any significant activity in coagulation, because Nemerson et al'9 have shown that VI1 has only about I % of the activity of VIIa in cleaving F.X. Two experimental findings reported here further support the hypothesis that R152Q lacks coagulant activity. First, Activity of activated species in the presence of increasing concentrations of TF. Equal concentrations of the activated species are incubated with a specific concentration of TF for 5 minutes. The amount of activity is a function of the concentration of the Vlla-TF complex, which cleaves substrate 100 times more rapidly than Vlla alone. For R79Q, a higher concentration of TF is required t o achieve the same level of activity as for wild type. 1 .1 Wild-type; 1 .1 R79Q.
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immunoblotting of patient plasma F.VII after activation with Xa discloses absence of the normal activation pattern (Fig   4) . Second, anaylsis of the R152Q recombinant protein in a clotting assay discloses that the protein has no activity in coagulation. Even at concentrations 10-fold higher than plasma, the PT remains prolonged at 41 seconds (see Table  3 ). Taken together, the previously reported findings and our experimental findings support the view that the R152Q protein cannot be activated normally and does not have activity in coagulation. This is consistent with the hypothesis that the F.VII zymogen lacks coagulant activity.
We next wished to determine whether the R79Q mutation had any effect on coagulant activity. This mutation occurs in the first EGF-like domain, in a highly conserved region. In the loop defined by the two cysteines at residues 72 and 81 (F.VII numbering), 6 of the 10 residues are invariant, and two others, including the residue at amino acid 79, show conservation of the type of amino acid (small neutral, basic, etc). Based on studies implicating the first EGF-like domain in binding to TF?" we hypothesized that a change from a basic to a neutral residue at amino acid 79 would result in a compromise in function. To test this hypothesis, it was necessary to analyze the R79Q mutation independently (ie, without the presence of the R152Q mutation). This was achieved by using site-directed mutagenesis to prepare a recombinant F.VII molecule (rF.VI1) containing only the R79Q mutation. This molecule was abnormal in four different assays: a clotting assay in reconstituted plasma (Table  3) ; a time course of activation by purified Xa (Fig  8) ; an assay for TF binding on a solid matrix (Fig 7) ; and an amidolytic assay for VIIa activity in the presence of increasing concentrations of TF (Fig 9) . In the reconstituted plasma assay, purified rF.VI1 was added in varying concentrations to F.VII-deficient plasma and a PT was determined. At concentrations closest to that of plasma (second and third rows in Table 3 ), the R79Q variant gives markedly prolonged PTs when compared with the wild-type. As the concentration of F.VII is increased, the difference between wild-type and R79Q narrows, so that at 5,000 ng/mL (=lO-fold normal concentration), there is no significant difference in PTs. Thus, whatever the defect in coagulation caused by the R79Q variant, it can be overcome by increasing the concentration of the mutant protein. Possible mechanisms underlying these findings in the clotting assays include a reduced rate of activation of the mutant VII, reduced activity of the activated species, or both. Studies with the R79Q variant demonstrate a reduced rate of activation compared with wild-type recombinant F.VII. There is no difference between wild-type and R79Q in amidolytic activity of the activated species, when measured in the absence of TF or under conditions where TF is saturating. As shown in Fig 9, though, there is a marked difference in the activity of activated wild-type or R79Q in the presence of lower concentrations of TF. The likely explanation for these observations can be found in the TF binding assays, which demonstrate a reduced binding to TF for both the patient plasma and the R79Q protein. The plasma results (on a molecule containing both the R79Q defect and the R152Q defect) were markedly abnormal in the TF binding assay described here. Testing of the recombinant proteins in the TF binding assay showed nearly equivalent results for wild-type F.VII and the R152Q mutant, but markedly reduced binding for the R79Q molecule. In other experiments, we have shown that the affinity of the zymogen form of R79Q for TF is markedly reduced compared with the affinity of wild-type F.VII, wild-type F.VIIa, and activated R79Q for T F .
4 ' Taken together, these findings imply that it is the R79Q mutation that accounts for the abnormal result obtained with patient plasma in the TF binding assay. The difference in TF binding between the plasma sample and the recombinant protein (the former is virtually nil; the latter is reduced but detectable) appears to be due to the fact that the plasma VII, bearing the R152Q mutation as well as the R79Q, cannot be activated, whereas the R79Q recombinant protein can (albeit more slowly than wild-type).
Based on a preliminary report of the data reported herein, Kazama et a14' have synthesized and studied a recombinant R79Q variant. Some but not all of their observations agree with those reported here. In accord with our data, they noted normal activity of the R79Q F.VII, once activated. They also noted normal activation of R79Q by factor Xa when tested at a concentration of 1 pmoVL (-50,000 ng/mL, or 10-fold higher than the highest concentration that we tested). They did not test activation at lower, more physiologic F.VII concentrations. Their data are in agreement with our observation (shown in Table 3 ) that high concentrations of F.VII can abolish the difference between wild-type and R79Q proteins in a clotting assay. Using a different approach to analysis of TF binding, they have suggested that R79Q binds normally to TF. In their investigation, 582 cells, a human bladder carcinoma cell line, are used as a source of TF. F.VII is added to the cells, and subsequently F.X is added; the F.Xa formed is measured using a chromogenic substrate. Using this assay, they were unable to distinguish any difference between plasma F.VII and R79Q F.VII. Recently, Takamiya et ai4' have described a patient who is homozygous for the R79Q mutation and has no other defect in the F.VII gene. This patient has an F.VI1 activity level of 20%. These data are entirely consistent with our analysis of the R79Q recombinant but are difficult to reconcile with the findings of Kazama et al. ' " A potential drawback of our analysis of the recombinant proteins is that they were not fully y-carboxylated (-7310 Gla residues). However, all results were compared with results obtained on analysis of wild-type recombinant F.VII, and both R79Q and R152Q had Gla content greater than or equivalent to that of wild-type. Thus, it seems unlikely that the abnormalities present on functional assays of the mutant proteins are caused by undercarboxylation, because the wildtype protein, with an equivalent Gla content, does not display these findings (eg, prolonged clotting times, altered binding to TF). To exclude the possibility that differences in function reflected differences in carboxylation at specific Gla residues, N-terminal sequence analysis was performed on the wild-type and R79Q proteins. Results showed that carboxylation was 290% at 9 of 10 Gla residues in both proteins (the 10th Gla residue, at amino acid 35, was too far in to be analyzed). Thus, differences among the proteins appear to result from the mutation installed, not from differences in carboxylation at specific residues.
A number of studies have been performed aimed at identifying the region(s) of F.VIIa required for interaction with TF; thus far, no clear consensus on the primary structural determinants of F.VIIa binding to T F has emerged.h.s.y.""~. 43 The results presented in the current report, showing reduced binding to TF for the R79Q mutant and for the patient's plasma, support the concept that the first EGF-like domain is required for T F binding. It is likely that the binding of F.VIIa to T F involves multiple sites, including the EGF-like domains and the heavy chain, and that a conformational change mediated by the Gla domain is also required.
In summary, we have described a patient with severe F.VII deficiency who is homozygous for two mutations in the F.VII gene, an R79Q substitution in the first EGF-like domain and an R152Q change at the cleavage site for activation. Study of patient plasma shows a prolonged clotting time and reduced binding to TF in an in vitro assay. Analysis of recombinant F.VII molecules containing only one or the other of these substitutions was undertaken to determine how each mutation contributed to these findings. Analysis of the R152Q mutation showed that it had virtually no activity in coagulation (in a PT assay) but bound essentially normally to TF. The R79Q mutation, on the other hand, resulted in only a modest prolongation of the PT (compared with wild-type recombinant) but a reduced binding to TF. The results with the R79Q mutant suggest that the first EGF-like domain is required for binding to TF. The results with the R152Q mutant are consistent with the hypothesis that F.VII zymogen lacks activity and requires activation for expression of biologic activity. The results of the nucleic acid analysis, and the functional studies on the patient protein and the recombinants, suggest that the R152Q mutation alone could account for the patient's phenotype. In the presence of the severe defect caused by the R 152Q mutation, the effect of the R79Q mutation cannot be assessed. Our data with the recombinants indicate that the R79Q mutation alone (ie, in the absence of R152Q) would also result in a bleeding diathesis, milder than that seen in this patient. A recent report of such a patient (homozygous for R79Q with no other defect)42 confirms our prediction.
Perhaps the most intriguing aspect of this analysis is the opportunity it affords to make clinical observations on a patient who essentially lacks a functioning TF/F.VII pathway ( < l % F.VII activity and a F.VII protein that cannot be activated). In the current view, the extrinsic pathway initiates coagulation and the intrinsic pathway amplifies and maintains it. The clinical histories of patients with hemophilia A and B make it clear that the extrinsic pathway cannot compensate fully for defects in the intrinsic pathway. This patient's clinical history suggests that the reverse is also true, ie, that the intrinsic pathway cannot fully compensate for defects in the extrinsic pathway. Early in life, this patient suffered a devastating intracranial bleed that left him with a severe spastic paraparesis and mild mental retardation. He has been confined to a wheelchair since childhood. It is likely that this severe limitation in his level of activity has modified the course of his disease, but even in the face of this restricted activity, he has bleeds severe enough to require replacement therapy approximately once a month. It would appear that neither pathway alone can provide adequate hemostasis independent of the other.
